WECOME Pharmaceuticals released its performance for the first three quarters, with a net loss attributable to the parent company of 124 million yuan
According to the Zhitong Finance APP, WECOME released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 151 million yuan, a year-on-year decrease of 59.20%. The net loss attributable to shareholders of the listed company was 124 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 122 million yuan. The basic loss per share was 0.8554 yuan
According to the Zhitong Finance APP, WECOME (300878.SZ) released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 151 million yuan, a year-on-year decrease of 59.20%. The net loss attributable to shareholders of the listed company was 124 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 122 million yuan. The basic loss per share was 0.8554 yuan
